
Adalimumab outperformed other biologics in efficacy and safety for moderate-to-severe hidradenitis suppurativa (HS). In a network meta-analysis of 2,731 patients, adalimumab showed superior efficacy (OR=1.74) and fewer adverse events compared to secukinumab and bimekizumab. With significant efficacy over secukinumab and fewer adverse events than bimekizumab, adalimumab proved to be the best treatment option for HS in phase III trials.
Like
Save
Share